# CSA Medical, Inc.

> CSA Medical is a Lexington, Massachusetts medical device company that develops spray cryotherapy technology for the lungs. Its flagship RejuvenAir System delivers a metered dose of -196°C liquid nitrogen through a bronchoscope to destroy the damaged, mucus-producing cells that drive chronic bronchitis in COPD patients, while preserving the underlying tissue matrix so healthy airway cells can regrow. Backed by roughly $161M in total funding including a $53M Series D in 2024, the company submitted its FDA PMA in January 2026 following a successful pivotal SPRAY-CB trial.

- **Headquarters:** Lexington, Massachusetts, United States
- **Team size:** ~33 employees
- **Products:** RejuvenAir System, truFreeze / trūFreeze Spray Cryotherapy System
- **Notable:** Raised an oversubscribed $53M Series D in September 2024 to fund FDA PMA and U.S. commercialization., Completed enrollment in the SPRAY-CB U.S. pivotal trial (210 patients) nearly two months ahead of schedule in July 2024., SPRAY-CB met its primary endpoint and multiple secondary endpoints with statistical significance and a favorable safety profile.

## Products & services

- **RejuvenAir System** — A bronchoscopic Metered CryoSpray (MCS) therapy that delivers precisely controlled doses of -196°C liquid nitrogen to targeted airway tissue in COPD patients with chronic bronchitis. It destroys damaged cilia and mucus-producing goblet cells while preserving the extracellular matrix, enabling regrowth of healthy epithelium. No implant is left behind.
- **truFreeze / trūFreeze Spray Cryotherapy System** — An endoscopic liquid nitrogen spray cryotherapy platform, FDA cleared for ablation of unwanted tissue in the gastrointestinal tract including Barrett's esophagus with low- and high-grade dysplasia. The most widely used endoscopic cryospray ablation system, with over 11,000 treatments performed. The GI cryotherapy business was later divested to STERIS.

## Achievements

- Raised an oversubscribed $53M Series D in September 2024 to fund FDA PMA and U.S. commercialization.
- Completed enrollment in the SPRAY-CB U.S. pivotal trial (210 patients) nearly two months ahead of schedule in July 2024.
- SPRAY-CB met its primary endpoint and multiple secondary endpoints with statistical significance and a favorable safety profile.
- Submitted FDA Premarket Approval (PMA) application for the RejuvenAir System in January 2026.
- Received FDA Breakthrough Device Designation for RejuvenAir.
- Secured CE mark approval in Europe for RejuvenAir to treat COPD with chronic bronchitis.
- Completed more than 500 Metered CryoSpray procedures.
- truFreeze became the most widely used endoscopic cryospray ablation system with 11,000+ treatments before divestiture.

## Latest updates

- **2026-01** — Submitted FDA Premarket Approval (PMA) application for the RejuvenAir System following positive pivotal SPRAY-CB trial results.
- **2024-10** — Presented data correlating airway remodeling ('rejuvenation') with positive clinical outcomes.
- **2024-09** — Closed oversubscribed $53M Series D co-led by TVM Capital Life Science and Yonjin Ventures; presented new metered cryospray efficacy data at European conferences.
- **2024-07** — Completed enrollment in the SPRAY-CB pivotal trial ahead of schedule.

## Links

- Website: https://rejuvenair.com
- LinkedIn: https://www.linkedin.com/company/csa-medical-inc
- Facebook: https://www.facebook.com/Chronic-Bronchitis-Clinical-Study-101228994783891/

---

Profile page: https://yespress.io/csa-medical-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-21